BioSpace News Archive

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.

Sequencing by synthesis (SBS), is one of the most influential and greatly adopted DNA sequencing technologies used by researchers and scientists globally.

AB Science SA publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders.

Ending the COVID-19 pandemic will require most Americans to be vaccinated. Yet vaccination has become politically polarized, with Republicans being the most consistently hesitant, and the gap in vaccination rates between U.S. counties that voted for Joe Biden and those that voted for Donald Trump continuing to grow.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company approved the grant of equity awards to three new employees with a grant date of August 2, 2021, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on August 2, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 15,938 shares of Puma common stock to three new non-executive employees.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the BTIG Biotechnology Conference being held virtually August 9-10, 2021.

Synedgen, a biotechnology company using glycopolymer chemistry to develop therapeutics that enhance and control signaling in the innate immune system, today announced the initiation of a randomized controlled trial (RCT) to test the safety and effectiveness of SynePure™ Wound Cleanser (SynePure) in combination with Catasyn™ Advanced Technology Hydrogel (Catasyn) for the treatment of superficial partial-thickness burn wounds.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Further details relating to the change of auditor can be found in the Company’s press release dated July 12, 2021. Further details relating to the change of auditor can be found in the Company’s press release dated July 12, 2021.